New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on December 1, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director John Morikis has made a significant investment in Johnson & Johnson by purchasing 1,250 shares of the company’s stock, valued at $257,687.
Recent Updates on JNJ stock
In the last 24 hours, Johnson & Johnson (J&J) has seen significant developments, particularly with the FDA approval of its drug DARZALEX Faspro for a new indication, specifically for high-risk smoldering multiple myeloma (HR-SMM). This regulatory milestone is likely a key factor in Scotiabank’s recent initiation of coverage on J&J with an Outperform rating and a price target of $230. The FDA approval is expected to enhance J&J’s oncology portfolio, potentially driving future revenue growth and positively influencing the stock’s valuation.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson’s strong financial performance and positive earnings call guidance are the most significant factors driving the stock score. The technical analysis supports a bullish outlook, while the valuation reflects a stable but not undervalued position. The company’s strategic focus on high-growth areas and successful product launches further enhance its prospects.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 47.46%
Average Trading Volume: 8,732,115
Technical Sentiment Signal: Buy
Current Market Cap: $498.5B